vaxxitek® hvt + ibd + nd
Bursal Disease-Marek's disease-Newcastle disease vaccine, serotype 3, live Marek's disease vector; the vaccine includes a diluent
Search
Partnership with Precision Health Research, Singapore
Boehringer Ingelheim joins forces with Precision Health Research, Singapore with the aim of transforming healthcare and improving patient outcomes in Singapore and beyond.
Saving Stroke Patients around the world
Suffering a stroke is one of the most devastating medical emergencies that can happen to a person. Over 15 million people worldwide suffer a stroke every year.
Pioneering for progress in generalized pustular psoriasis
An event, bringing together 170 delegates from across the world to strive for excellence in care of GPP
Glyxambi®
Treatment of type 2 diabetes mellitus to improve glycaemic control in adults when treatment with both empagliflozin and linagliptin is appropriate (US).
Acquisition expands research in cancer immunology
Boehringer Ingelheim acquires Abexxa to develop novel cancer therapies by leveraging Abexxa’s unique technology and breakthrough antibody-based drugs.
A life in a day: the reality of living with lung cancer
Within the initiative “A life in a day”, Anna-Maria spent 24 hours in the shoes of a lung cancer patient to better understand the patient experience.
Actilyse®
Fibrinolytic treatment of acute ischaemic stroke, acute myocardial infarction, acute massive pulmonary embolism. Fibrinolytic treatment of occluded catheters.
EMA filing acceptance and validation for spesolimab
The European Medicines Agency has accepted and validated the marketing authorization application for spesolimab in generalized pustular psoriasis
Patient centricity and site centricity in clinical trials
We are partnering with patients, caregivers and trial site staff to design and conduct our clinical trials, to provide a better experience for all.
discontinuation-bi-1467335-diabetic-retinopathy
The discontinuation of the development of BI 1467335 in diabetic retinopathy has been announced
Patient Organizations
Boehringer Ingelheim’s core principles and vision guide our work with patient organisations.
collaboration criving innovation
In conversation with Dr. Megan Grether, Global Head of Business Development & Licensing, Boehringer Ingelheim Animal Health.
In-Reach Africa initiatives successfully completed
We are proud to report the successful completion of Kuza Afya and Tiba Yako, two of our In-Reach Africa initiatives.
2020 European PRRS Research Award sponsorship
2020 European PRRS Research Award: Boehringer Ingelheim calls for submissions
Judi – My Asthma Journey
Partnership Boehringer Ingelheim Lifebit health data
Boehringer Ingelheim and Lifebit announce partnership to capture transformational value of health data
Sarcoma
Hear from Gary Schwartz, MD, Director of the Case Comprehensive Cancer Center, Cleveland, Ohio, talk about his expert perspectives on sarcoma.
Science Focus
Science Focus
Micardis®
Treatment of hypertension. For the reduction of the risk of myocardial infarction (heart attack), stroke or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take A
Poultry
Poultry
New spesolimab data show significant improvement in GPP flares
New spesolimab data show significant improvement in GPP flares
Spesolimab prevents GPP flares
Spesolimab prevents generalized pustular psoriasis flares in EFFISAYIL™ 2 trial
Jentadueto®
Treatment of type 2 diabetes mellitus to improve glycaemic control in adults when treatment with metformin does not lead to sufficient control or when patients are treated with trajenta® (linagliptin) and metformin.
Synjardy®
Treatment of type 2 diabetes mellitus to improve glycaemic control in adults when treatment with metformin does not lead to sufficient control or when patients are treated with jardiance® (empagliflozin) and metformin.